CBER’s New Director “Marks” A New Era For Biologics Regulation

This article was originally published in RPM Report

21 Jan 2016
Analysis

Cole Werble cole.werble@previsionpolicy.com

Executive Summary

Peter Marks takes over the top spot in the center for biologics at FDA after a four year training period as deputy director. His background appears well suited to what promises to be a transformative era in medicine.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Subjects
Regulation

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS079887

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS079887

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

CBER’s New Director “Marks” A New Era For Biologics Regulation

Analysis

Executive Summary

Related Content

FDA's Califf Seeks His First Big Hire: Chief Scientist

FDA Chief Scientist Post A Chance For Califf To Make Mark

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert